Quick Answer
TransMedics Group, Inc. reported R&D Expense of $69.06 million for fiscal year 2025.
TransMedics Group, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $69.06M | +23.4% |
| 2024 | $55.97M | +55.2% |
| 2023 | $36.05M | +34.5% |
| 2022 | $26.81M | +20.2% |
| 2021 | $22.30M | +18.4% |
| 2020 | $18.83M | -5.2% |
| 2019 | $19.87M | +45.5% |
| 2018 | $13.66M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $15.26M | +7.0% | -4.2% |
| June 30, 2025 | $15.93M | +15.0% | -7.1% |
| March 31, 2025 | $17.16M | +50.8% | +20.3% |
| September 30, 2024 | $14.27M | +28.2% | +2.9% |
| June 30, 2024 | $13.86M | +67.1% | +21.8% |
| March 31, 2024 | $11.38M | +93.8% | +2.2% |
| September 30, 2023 | $11.13M | +63.5% | +34.3% |
| June 30, 2023 | $8.29M | +23.5% | +41.2% |
- TransMedics Group, Inc. showed an increase of +23.4% in R&D Expense compared to the prior fiscal year.
- Over the 2018–2025 period, TransMedics Group, Inc.’s r&d expense has grown by 405.7% (from $13.66 million to $69.06 million).
- The most recent figure is from TransMedics Group, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: